Regeneron Pharmaceuticals (REGN) Research & Development (2009 - 2026)

Regeneron Pharmaceuticals' Research & Development history runs 18 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• On a quarterly basis, Research & Development rose 16.28% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $6.1 billion, a 16.41% increase from a year earlier, with the FY2025 full-year figure at $5.9 billion, up 13.99% from the prior year.
• Research & Development slipped to $1.5 billion in Q1 2026 per REGN's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Research & Development topped out at $1.6 billion in Q4 2025 and bottomed at $794.3 million in Q2 2022.
• The 5-year median for Research & Development is $1.2 billion (2024), against an average of $1.2 billion.
• Across the five-year window, Research & Development soared 41.42% in 2022 and advanced 6.33% in 2025, its largest moves.
• Year by year, Research & Development stood at $1.0 billion in 2022, then gained by 12.86% to $1.2 billion in 2023, then climbed by 19.95% to $1.4 billion in 2024, then rose by 15.15% to $1.6 billion in 2025, then fell by 5.08% to $1.5 billion in 2026.
• Per Business Quant, the three latest REGN Research & Development figures stand at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.5 billion (Q3 2025).